WNT7A and sarcopenia: Specifically, the results showed a significant decrease in: (i) VEGF, the main regulator of angiogenesis, which explains the impairment of the circulatory system associated with sarcopenia [37], (ii) GAPDH, the main enzyme involved in the glycolytic pathway and negatively correlated with aging [27], and (iii) WNT7a, a central marker of skeletal muscle hypertrophy [26].